Navigation Links
TREVENTIS Corporation Closes $4.4 Million Financing with Wellcome Trust
Date:9/19/2013

PHILADELPHIA, Sept. 19, 2013 /PRNewswire/ -- TREVENTIS Corporation announced today that it received a $4.4 million Seeding Drug Discovery Award from the Wellcome Trust to continue development of a potentially disease-modifying drug for the treatment of Alzheimer's disease (AD). 

Recent studies demonstrate that the misfolding and subsequent aggregation of both beta-amyloid and tau are primary events in the Alzheimer's disease process.  Using a novel, proprietary drug design platform, TREVENTIS synthesized a class of organic drug-like molecules with the unique capability of binding to both beta-amyloid and tau, preventing aggregation of both proteins using a single drug. 

This financing supports the continued progression of TREVENTIS' compounds with the initial objective of delivering an AD drug candidate into first-in-man clinical testing.  The ultimate goal is to provide a drug that effectively and safely prevents the progression of AD.

"This financing signals a transformational event for TREVENTIS.  It provides the resources necessary to progress our critically important drug development and validates the scientific approach we have taken" said William McIntosh, Chairman and CEO, TREVENTIS. 

The principal investigator, board-certified neurologist and renowned medicinal chemist, Donald F. Weaver, MD, PhD, said: "I am deeply honored to receive this funding from the Wellcome Trust.  It enables us to advance important research that will profoundly and positively impact our efforts to treat people with chronic neurological dementias such as Alzheimer's."

About TREVENTIS Corporation 
TREVENTIS is headquartered in Southeastern Pennsylvania and has research operations in Toronto, Ontario, and Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying small molecule drugs for Alzheimer's and other protein misfolding diseases.  In addition to its therapeutic programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis and monitoring of treatment effects in Alzheimer's disease.  www.TREVENTIS.com

About Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health.  It supports the brightest minds in biomedical research and the medical humanities.  The Trust's breadth of support includes public engagement, education and the application of research to improve health.  It is independent of both political and commercial interests.  www.wellcome.ac.uk  U.S. Contact:  L. William McIntoshCanada Contact:  Dr. Mark ReedChairman and CEO, TREVENTISVP, Therapeutics, TREVENTISPhone: 610-488-608Phone: 647-924-9736wmcintosh@treventis.com  

mreed@treventis.com  


'/>"/>
SOURCE TREVENTIS Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Riley Exclusive Financial Advisor to Mirth Corporation in Connection with its Corporate Sale to Quality Systems, Inc.
2. Gentris Corporation Launches Next Generation Human Transcriptome Array
3. Euclid Systems Corporation signs agreement with Wenzhou Medical University to promote the use of Orthokeratology to control myopia progression
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Fourth Quarter
5. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
6. The X-Change Corporation To Announce Corporate Name Change Next Week; New Industry-Driven Branding to Commence For Global Activities, Services, Product Lines, and Website
7. Unilife Corporation To Announce Financial Results For Fiscal Year 2013 Fourth Quarter And Year End On Tuesday, September 10, 2013
8. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
9. MGC Diagnostics Corporation Reports 2013 Third Quarter Operating Results
10. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
11. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):